CSI Market
Sign In | Register

Immunitybio inc (IBRX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IBRX quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Immunitybio inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-351.47
Depreciation & amortization15.53
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-6.33
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation36.81
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-49.09
Non Cash Interest Items From Operating Activities-
Non Cash Interest Income Expense From Operating Activities-
Forgiveness Of Note Receivable From Related Party-
Marketable Securities Gain Loss-
Operating Lease Right Of Use Asset Amortization-
Increase Decrease In Operating Lease Right Of Use Asset-
Operating Lease Right Of Use Asset Non Cash Lease Expense-
Increase Decrease In Operating Lease Right Of Use Asset Net-
Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount-
Increase Decrease In Operating Lease Liability-3.75
Equity Securities Fv Ni Unrealized Gain Loss-
Interest Expense Other Debt-
Change In Fair Value Of Derivative Liabilities-6.40
Fair Value Option Changes In Fair Value Gain Loss42.77
Interest Expense Nonoperating Secured Debt Net41.23
Increase Decrease In Due To Related Parties Current And Non Current0.48
Increase Decrease In Due To Related Parties Current And Non Current0.48
Income taxes0.57
Unrealized Gain (Loss) on Investments0.00
Accounts Receivable-37.03
Increase (Decrease) in Accounts Payable, Trade-0.19
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-7.07
Other Working Capital0.80
Other Noncash Income (Expense)-0.25
Other net0.00
Payments for (Proceeds from) Other Operating Activities17.97
Discontinued operations0.00
Net Cash flow from Operating Activities-304.94
Investing Activities
Capital Expenditures-4.25
Sale of Capital Items0.00
Short-term Investments Proceeds95.82
Payments to Acquire Available-for-sale Securities, Debt-241.37
Real Estate Investments0.00
Payments To Acquire Cost Method Investment-
Payments To Acquire Investments In Equity Securities-
Payment To Affiliate To Facilitate Divestiture Of Interest-
Payments To Acquire Non Marketable Equity Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Payments to Acquire Interest in Joint Venture0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-149.80
Financing Activities
Short-term debt Net2.88
Other borrowing transactions0.00
Long-term debt - borrowings-1.13
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock400.78
Proceeds from Contributions from Affiliates0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-146.18
Recovery Of Financing Costs-
Proceeds From Exercise Of Stock Options And Warrants-
Proceeds From Debt And Equity Offerings Net Of Issuance Costs-
Payments For Principal Of Financing Obligations-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Finance Lease Principal Payments-0.03
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations143.91
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities400.24
Effect of exchange rate on cash flow0.02
Discontinued operations0.00
Free Cash Flow-309.19
Total Cash Flow-54.48
4 historic quarters locked

Sign in to unlock the full Immunitybio inc cash flow history.

Sign In Create Free Account

About Immunitybio Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 23, 2026
  • Source: ibrx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001326110-26-000030

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License